Kintara Therapeutics, Inc. (KTRA)
Market Cap | 6.62M |
Revenue (ttm) | n/a |
Net Income (ttm) | -19.22M |
Shares Out | 1.68M |
EPS (ttm) | -14.60 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 14,029 |
Open | 3.67 |
Previous Close | 3.64 |
Day's Range | 3.67 - 3.95 |
52-Week Range | 2.80 - 42.00 |
Beta | 1.00 |
Analysts | Sell |
Price Target | 153.00 (+3,773.42%) |
Earnings Date | Feb 14, 2023 |
About KTRA
Kintara Therapeutics, Inc., a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients. It is developing two late-stage, Phase III-ready therapeutics, including VAL-083, a DNA-targeting agent for the treatment of drug-resistant solid tumors, such as glioblastoma multiforme, as well as other solid tumors, including ovarian cancer, non-small cell lung cancer, and diffuse intrinsic pontine glioma; and REM-001, a photodynamic therapy for the treatment of cutaneous metastatic b... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 7 analysts, the average rating for KTRA stock is "Sell." The 12-month stock price forecast is $153.0, which is an increase of 3,773.42% from the latest price.
News

Kintara Therapeutics to Present Two Posters at the 2023 American Association for Cancer Research Annual Meeting
SAN DIEGO , March 15, 2023 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer ther...

Kintara Therapeutics Scheduled to Present at Two Conferences the Week of March 13, 2023
-35th Annual ROTH Conference, March 12-14, 2023 – -4th Annual Glioblastoma Drug Development Summit, March 14-16, 2023- SAN DIEGO , March 10, 2023 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KT...

Kintara Therapeutics Announces Fiscal 2023 Second Quarter Financial Results and Provides Corporate Update
SAN DIEGO , Feb. 14, 2023 /PRNewswire/ -- Kintara Therapeutics, Inc. (NASDAQ: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer thera...

Kintara Therapeutics to Present at the 2023 BIO CEO & Investor Conference
SAN DIEGO , Jan. 30, 2023 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer thera...

Kintara Therapeutics to Present at the Biotech Showcase Conference on January 10, 2023
SAN DIEGO , Jan. 9, 2023 /PRNewswire/ -- Kintara Therapeutics, Inc. ( Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer thera...

Is Kintara Therapeutics A Hidden Gem?
Kintara Therapeutics' earnings are in the red but impressive FDA approvals could satisfy an extreme upside potential to bring them solvent by next year.

Why Kintara Therapeutics Stock Is Seeing Blue Skies Thursday - Kintara Therapeutics (NASDAQ:KTRA)
Kintara Therapeutics Inc KTRA shares are trading higher by 24.09% to $9.94 Thursday morning after the company received FDA Orphan Drug Designation (ODD) for VAL-083.

Kintara Therapeutics Receives Orphan Drug Designation for VAL-083 for Treatment of Diffuse Intrinsic Pontine Glioma (DIPG)
SAN DIEGO , Dec. 15, 2022 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer thera...

Kintara Therapeutics to Participate at the RHK Capital Disruptive Growth Conference on December 5-6, 2022
SAN DIEGO , Dec. 1, 2022 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therap...

Kintara Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
SAN DIEGO , Nov. 30, 2022 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer thera...

Kintara Therapeutics Granted Fast Track Designation from FDA for REM-001 for Cutaneous Metastatic Breast Cancer
SAN DIEGO , Nov. 28, 2022 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer thera...

Kintara Therapeutics Presents Three Posters at the 2022 Society for Neuro-Oncology Annual Meeting
SAN DIEGO , Nov. 18, 2022 /PRNewswire/ -- Kintara Therapeutics, Inc.(Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therap...

Kintara Announces One-for-Fifty Reverse Stock Split
SAN DIEGO , Nov. 11, 2022 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer thera...

Kintara Therapeutics Announces Fiscal 2023 First Quarter Financial Results and Provides Corporate Update
SAN DIEGO , Nov. 9, 2022 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therap...

Kintara Therapeutics Pauses REM-001 Program to Conserve Funds to Support VAL-083 International Registrational Study
REM-001 15-Patient Study Paused to Conserve Funds – Approximately $3 Million Saved through 2023 SAN DIEGO , Oct. 19, 2022 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "C...

Kintara Therapeutics Announces Fiscal 2022 Financial Results and Provides Corporate Update
SAN DIEGO , Sept. 27, 2022 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer ther...

Kintara Therapeutics Announces Three Abstracts Have Been Accepted for the 2022 Society for Neuro-Oncology Annual Meeting
SAN DIEGO , Sept. 8, 2022 /PRNewswire/ -- Kintara Therapeutics, Inc.(Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therap...

Kintara Therapeutics Receives Study May Proceed Letter from the FDA for REM-001 for Cutaneous Metastatic Breast Cancer
SAN DIEGO , Aug. 9, 2022 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therap...

Kintara Therapeutics Enters Into Equity Purchase Agreement for Up to $20 Million with Lincoln Park Capital
SAN DIEGO , Aug. 3, 2022 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) (Kintara or the Company), a biopharmaceutical company focused on the development of new solid tumor cancer therapies,...

Kintara Therapeutics to Present at the Alliance Global Partners Summer Healthcare Conference
SAN DIEGO , June 21, 2022 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer thera...

Why Kintara Therapeutics Shares Are Skyrocketing Today
Kintara Therapeutics Inc (NASDAQ: KTRA) shares are trading higher by 28.6% to $0.24 after the FDA granted Fast Track Designation to the company's VAL-083. Fast Track is a process designed to facilitat...

Kintara Therapeutics Granted Fast Track Designation from the FDA for VAL-083 for Newly-Diagnosed Glioblastoma
SAN DIEGO , June 15, 2022 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer thera...

Kintara Therapeutics to Present at the JMP Securities Life Sciences Conference
SAN DIEGO , June 10, 2022 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer thera...

Kintara Granted 180-Day Extension to Meet Nasdaq Minimum Bid Price Requirement
SAN DIEGO , June 3, 2022 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therap...

Kintara Announces First European Site Activation in Switzerland in GCAR Phase 2/3 Clinical Trial for Glioblastoma
SAN DIEGO , May 27, 2022 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therap...